Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus XOSPATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus XOSPATA.
ARRANON vs XOSPATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
Gilteritinib is a tyrosine kinase inhibitor that inhibits FLT3 (FMS-like tyrosine kinase 3) receptor signaling, including FLT3-ITD and FLT3-TKD mutations, leading to apoptosis in leukemic cells.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
120 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Terminal half-life 9.1 hours (range 4.4–16.1 hours); supports once-daily dosing.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Fecal (64%) and renal (16%) as metabolites; <1% unchanged in urine.
Category C
Category C
Antineoplastic
Antineoplastic